Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
The UK medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA) has approved the marketing authorisation for lecanemab in the treatment of early Alzheimer’s disease. However, the treatment will not be available through the National Health Service (NHS), the UK’s publicly funded health agency.
The research, commissioned by The Lancet revised their 2020 findings to include failing eyesight and high LDL cholesterol as risk factors for dementia.
At the beginning of World Alzheimer's Month, ADI highlights evidence that the COVID-19 pandemic is leading to extremely high death rates amongst people with dementia globally.
The Dominican Republic’s Ministry of Public Health announces that the country will be launching a national dementia plan.
ADI's Global Perspective for July 2020 now available.
The German Government announces that a national dementia strategy has been officially adopted.
Alzheimer’s Disease International (ADI) and ITN Productions have co-produced a new documentary ‘Hope in the Age of Dementia'.
The following piece is from our third 'From Plan to Impact' report and written by ADI's Communications and Policy Manager, Annie Bliss, the main author of the report. In this piece, she writes about the impact of the COVID-19 pandemic on diagnostic, treatment, care and support services for people living with dementia.
A new report by ADI calls on world governments to ensure that dementia remains a priority during and after the COVID-19 pandemic.
Catherine Hall, Chief Executive of Alzheimers New Zealand, writes about how Alzheimers New Zealand has responded and adapted to COVID-19, both in the first weeks of lockdown and today.